Brind.
  1. FibroGen received positive feedback from the FDA on a Type C meeting and increased the transaction consideration for the sale of FibroGen China.

Positive Type C meeting supports advancement of roxadustat.

2 reports, 1 independent Updated Aug 7
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Positive Type C meeting supports advancement of roxadustat.

Who's involved

What this event is mainly about
FDAFibroGen (United States)

Keep exploring

Part of

FibroGen received positive feedback from the FDA on a Type C meeting and increased the transaction consideration for the sale of FibroGen China. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireFibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes FibroGen has reached agreement with the FDA on impo
  • GlobeNewswireFibroGen to Report Second Quarter 2025 Financial Results SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2025 financial results on Monday,